Abatacept therapy and safety management (Q38006176)

26 August 2017

Abatacept therapy and safety management (English)

1 reference

26 August 2017

8

Cécile Gaujoux-Viala

0 references

Thierry Schaeverbeke

22

Thierry Schaeverbeke

1 reference

26 August 2017

Jean-Pierre Marolleau

15

Jean-Pierre Marolleau

0 references

Pascal Richette

Pascal Richette

20

0 references

Hervé Bachelez

Hervé Bachelez

2

0 references

Éric Hachulla

Eric Hachulla

13

0 references

Xavier Puéchal

Xavier Puéchal

19

0 references

Bruno Fautrel

7

Bruno Fautrel

1 reference

26 August 2017

3

Jean-Marie Berthelot

1 reference

26 August 2017

23

Martin Soubrier

1 reference

26 August 2017

10

Laure Gossec

1 reference

26 August 2017

26

Daniel Wendling

1 reference

26 August 2017

21

Alain Saraux

1 reference

26 August 2017

27

Xavier Mariette

1 reference

26 August 2017

5

Pascal Claudepierre

1 reference

26 August 2017

11

Philippe Goupille

1 reference

26 August 2017

28

Jean Sibilia

1 reference

26 August 2017

9

Vincent Goëb

1 reference

Séverine Guillaume-Czitrom

26 August 2017

12

Séverine Guillaume-Czitrom

1 reference

26 August 2017

24

Manuelle Viguier

1 reference

26 August 2017

25

Olivier Vittecoq

1 reference

26 August 2017

14

Thierry Lequerré

1 reference

26 August 2017

Thao Pham

1

1 reference

26 August 2017

Jacques Blacher

4

1 reference

26 August 2017

Arnaud Constantin

6

1 reference

26 August 2017

Cécile Gaujoux-Viala

8

1 reference

26 August 2017

Jean-Pierre Marolleau

15

1 reference

26 August 2017

Valérie Martinez

16

1 reference

26 August 2017

Charles Masson

17

1 reference

26 August 2017

Luc Mouthon

18

1 reference

26 August 2017

1 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

79 Suppl 1

1 reference

26 August 2017

3-84

1 reference

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

TNF alpha antagonist therapy and safety monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Immunomodulation in the treatment of haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Mortality in established rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Comorbidities in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Safety profile of abatacept in rheumatoid arthritis: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Abatacept treatment for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

The risk of infections with biologic therapies for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Cytokines and T cells in host defense

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Role of T cell costimulation in anti-viral immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Costimulation in resistance to infection and development of immune pathology: lessons from toxoplasma

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

The host response of CD28-deficient mice to Pneumocystis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Biological agents in kidney transplantation: belatacept is entering the field

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Five-year safety and efficacy of belatacept in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Perioperative management of asplenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Inhibition of T cells provides protection against early invasive pneumococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Costimulation blockade in rheumatic diseases: where we are?

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

CTLA-4 directly inhibits osteoclast formation

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Costimulatory molecules in human periodontal disease tissues.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Antibiotic prophylaxis in dentistry: a review and practice recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Transmission disequilibrium of maternally-inherited CTLA-4 microsatellite alleles in idiopathic recurrent miscarriage

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

The CTLA-4 gene is expressed in placental fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Fetal tolerance in human pregnancy--a crucial balance between acceptance and limitation of trophoblast invasion

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Blockade of CD80 and CD86 at the time of implantation inhibits maternal rejection to the allogeneic fetus in abortion-prone matings

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Association of the A/G polymorphism at position 49 in exon 1 of CTLA-4 with the susceptibility to unexplained recurrent spontaneous abortion in the Chinese population

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post-marketing study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

The mechanism underlying T cell help for induction of an antigen-specific in vivo humoral immune response to intact Streptococcus pneumoniae is dependent on the type of antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

The human antibody response to pneumococcal capsular polysaccharides is dependent on the CD40-CD40 ligand interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Preliminary definition of improvement in juvenile arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Abatacept as an option therapy in difficult to treat psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

T cells as therapeutic targets in SLE.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE)

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

CTLA4Ig alters the course of autoimmune disease development in Lyn-/- mice

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2812%2970011-8

7 January 2021

10.1016/S1297-319X(12)70011-8

Identifiers

DOI

1 reference

26 August 2017

1 reference